An observational study in Peripheral Artery Disease, sponsored by Acotec Scientific Co., Ltd. Recruiting at 7 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-01.
Sponsored by Acotec Scientific Co., Ltd · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.
Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 5th largest by planned enrollment of the 47 observational ones that give a count, is one of 5 that started in 2020, is one of 47 observational ones, reaches primary completion later than 10 of the 28 other live ones, and was the 125th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18–85
Biotronik AG · Sites in Germany, Austria, Belgium and 5 more countries
Ages 18+
CSL Behring · Sites in Germany, United States, Argentina and 32 more countries
Ages 18+
University of Leipzig · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 19 · Phase 4 5
First in 2001; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 107 across the 126 interventional studies, 200 across the 47 observational. Of the 118 that completed or were terminated, 34 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 173 have an industry lead sponsor. The 10 most frequent:
Acotec Scientific Co., Ltd is the lead sponsor of 17 studies on the registry; 8 are open to participants now.
Acotec Scientific Co., Ltd has 8 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971772Cardionovum GmbHSIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries | 2026-12 |
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT06832631OrbusNeichVITUS Post-Market Registry | 2027-06 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 173 studies in Peripheral Arterial Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
All-comers, prospective, multi-center, single-arm, non-interventional post market clinical follow-up (PMCF) Cohort 1 - Claudicants: Rutherford Clinical Category (RCC) 2-3 Cohort 2 - Critical Limb Ischemia: Rutherford Clinical Category (RCC) 4-6
To prospectively collect and assess safety and efficacy data on the AcoArt drug-coated PTA balloon catheters carrying the CE Mark per current Instructions for Use in a real-world cohort of patients with symptomatic arterial disease undergoing endovascular lower limb revascularization per the institution's standard practice.
patients with symptomatic arterial disease undergoing endovascular lower limb revascularization per the institution's standard practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rutherford Clinical Category (RCC) 2-3
Device: AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
critical limb ischemia,Rutherford Clinical Category (RCC) 4-6
Device: AcoArt Orchid (0.035"), AcoArt Tulip (0.018") and AcoArt Litos (0.014") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.
All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment
Primary efficacy endpoint - non-CLI group
Freedom from clinically-driven target lesion revascularization (CD-TLR) within 12 months after index procedure, which is defined as any re-intervention within the target lesion(s) due to recurrent clinical symptoms of PAD (increase of one Rutherford class or more) and/or drop of ankle-brachial index (≥20% or \>0.15 when compared with maximum early post-procedural level).
Time frame: 12 Months
Primary efficacy endpoint -CLI group
Freedom from clinically-driven TLR within 6 months after index procedure, which is defined as any re-intervention within the target lesion(s) due to delayed or worsening wound healing, new or recurrent wound, or worsening Rutherford class.
Time frame: 6 Months
Primary safety endpoint- non-CLI group
A composite of freedom from major adverse limb events and perioperative death (MALE-POD) through 30 days after index procedure. A major adverse limb event is defined as above-ankle amputation or major reintervention (ie, new bypass graft, major surgical graft revision such as a jump graft or an interposition graft, or thrombectomy/thrombolysis) of the treated limb.
Time frame: 30 days
Primary safety endpoint- CLI group
A composite of freedom from device- and procedure-related mortality, freedom from major target limb amputation and TLR within 12 months post-index procedure
Time frame: 12 Months
Rate of Any TLR (including clinically-driven and incidental TLR)
Any TLR (including clinically-driven and incidental TLR) at 6,12, 24, 36, 48, 60 months post-procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of Target vessel revascularization (TVR)
Target vessel revascularization (TVR) at 6, 12, 24, 36, 48, 60 months post-procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of Target limb revascularization
Target limb revascularization at 6, 12, 24, 36, 48, 60 months post-procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of CD-TLR
CD-TLR at 6, 24, 36, 48, 60 months post-procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of All-cause mortality
All-cause mortality at 6, 12, 24, 36, 48, 60 months post procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60months
Rate of Device- or procedure-related death
Device- or procedure-related death at 30 days and 6 months
Time frame: 30 days, 6 months
Rate of Major amputation
Major amputation at 6, 12, 24, 36, 48, 60 months post procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of Technical success
Technical success defined as final in-lesion residual diameter stenosis ≤50% by angiographic visual estimate at the end of the index procedure without device malfunction.
Time frame: Post procedure
Rate of Procedural success
Procedural success defined as technical success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or CD-TLR) prior to discharge
Time frame: Post procedure
Change in Rutherford clinical category (target limb)
Changes in Rutherford clinical category (target limb) at 6, 12, 24, 36, 48, 60 months post-procedure compared to baseline
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of primary sustained clinical improvement
Primary sustained clinical improvement, defined as improvement in Rutherford classification by one or more categories compared with baseline, without TLR.
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of secondary sustained clinical improvement
Secondary sustained clinical improvement, defined as improvement in Rutherford classification by one or more categories compared with baseline, including patients with TLR
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of (Major) Amputation-free survival - CLI group
(Major) Amputation-free survival at 6, 12, 24, 36, 48, 60 months post-procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of Minor amputation - CLI group
Minor amputation at 6, 12, 24, 36, 48, 60 months post-procedure
Time frame: 6 months,12 months,24 months, 36months,48 months,60 months
Rate of Wound healing - CLI group
healed or not; if not, improving, stagnant,worsening
Time frame: 60 months
New or recurrent wound of the target limb - CLI group
New or recurrent wound of the target limb
Time frame: 60 months
Started Jun 2020 (actual). Primary completion is estimated for Dec 2025, 65 months after the start.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 65 months is above that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acotec Scientific Co., Ltd